Perry M Elliott

List of Publications by Year
in descending order

492 papers	73,858 citations	1040 113 h-index	582 262 g-index
528 all docs	528 docs citations	528 times ranked	43679 citing authors

#	Article	IF	Citations
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
2	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
3	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
4	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 2015, 36, 2793-2867.	1.0	3,187
5	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.	1.0	2,656
6	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	1.0	2,436
7	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
8	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	1.0	2,280
9	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	1.0	2,176
10	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€¡. European Journal of Heart Failure, 2008, 10, 933-989.	2.9	1,893
11	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	13.9	1,558
12	2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal, 2018, 39, 1883-1948.	1.0	1,200
13	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118.	0.7	908
14	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	1.0	899
15	Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. Journal of the American College of Cardiology, 2000, 36, 2212-2218.	1.2	863
16	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	848
17	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021, 42, 17-96.	1.0	830
18	Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis. Circulation, 2010, 122, 138-144.	1.6	793

#	Article	IF	Citations
19	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	1.0	757
20	Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 56, 867-874.	1.2	720
21	Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance. Journal of the American College of Cardiology, 2003, 41, 1561-1567.	1.2	707
22	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	0.7	635
23	Hypertrophic cardiomyopathy. Lancet, The, 2004, 363, 1881-1891.	6.3	558
24	Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy. Circulation, 2002, 105, 1407-1411.	1.6	514
25	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 873-879.	1.2	484
26	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	6.3	481
27	Mutations in Cypher/ZASPin patients with dilated cardiomyopathy and left ventricular non-compaction. Journal of the American College of Cardiology, 2003, 42, 2014-2027.	1.2	479
28	Atlas of the clinical genetics of human dilated cardiomyopathy. European Heart Journal, 2015, 36, 1123-1135.	1.0	456
29	Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers. Journal of the American College of Cardiology, 2012, 59, 493-500.	1.2	449
30	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 420-424.	6.3	436
31	Natural history and familial characteristics of isolated left ventricular non-compaction. European Heart Journal, 2005, 26, 187-192.	1.0	427
32	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2010, 31, 2715-2726.	1.0	408
33	How to develop a more accurate risk prediction model when there are few events. BMJ, The, 2015, 351, h3868.	3.0	405
34	Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circulation: Cardiovascular Imaging, 2013, 6, 392-398.	1.3	399
35	Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease Evidence for a disease specific abnormality of the myocardial interstitium. European Heart Journal, 2003, 24, 2151-2155.	1.0	397
36	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary. Journal of the American College of Cardiology, 2020, 76, 3022-3055.	1.2	394

#	Article	IF	Citations
37	Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria?. European Heart Journal, 2007, 29, 89-95.	1.0	370
38	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	0.7	370
39	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, e159-e240.	1.2	364
40	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 1933-1941.	1.0	352
41	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care â€" Preliminary Report. New England Journal of Medicine, 2021, 385, 1868-1880.	13.9	352
42	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	1.0	346
43	European Society of Cardiology: cardiovascular disease statistics 2021. European Heart Journal, 2022, 43, 716-799.	1.0	343
44	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	13.7	338
45	Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2005, 45, 1251-1258.	1.2	323
46	Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. European Heart Journal, 2007, 28, 1228-1235.	1.0	320
47	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation, 2017, 135, 1357-1377.	1.6	319
48	Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. Nature Communications, 2015, 6, 8111.	5.8	300
49	Physiologic limits of left ventricular hypertrophy in elite junior athletes. Journal of the American College of Cardiology, 2002, 40, 1431-1436.	1.2	289
50	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. Journal of the American College of Cardiology, 2002, 40, 1445-1450.	1.2	285
51	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	3.9	278
52	Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart, 2012, 98, 1436-1441.	1.2	276
53	Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 1380-1384.	1.6	274
54	Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy. Circulation, 2010, 122, 1562-1569.	1.6	267

#	Article	IF	Citations
55	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation, 2020, 142, e558-e631.	1.6	263
56	Prospective Prognostic Assessment of Blood Pressure Response During Exercise in Patients With Hypertrophic Cardiomyopathy. Circulation, 1997, 96, 2987-2991.	1.6	263
57	Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. Journal of Medical Genetics, 2009, 46, 548-552.	1.5	259
58	Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. American Journal of Cardiology, 2001, 88, 275-279.	0.7	254
59	Mutations in the muscle LIM protein and Î±-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Molecular Genetics and Metabolism, 2003, 80, 207-215.	0.5	249
60	Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart, 2014, 100, 465-472.	1.2	248
61	Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet, The, 2009, 374, 1986-1996.	6.3	246
62	Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 1631-1641.	3.0	244
63	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. European Heart Journal, 2020, 41, 1414-1429.	1.0	239
64	Electrocardiographic changes in 1000 highly trained junior elite athletes. British Journal of Sports Medicine, 1999, 33, 319-324.	3.1	236
65	Evolving concepts in dilated cardiomyopathy. European Journal of Heart Failure, 2018, 20, 228-239.	2.9	233
66	Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2011, 123, 2701-2709.	1.6	226
67	Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1999, 33, 1596-1601.	1.2	221
68	Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2012, 33, 1128-1136.	1.0	220
69	Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2033-2040.	1.2	216
70	The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart, 2007, 93, 528-535.	1.2	211
71	Myotonic dystrophy: time for evidence-based therapy. European Heart Journal, 2014, 35, 2135-2137.	1.0	211
72	Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. Journal of Medical Genetics, 2013, 50, 228-239.	1.5	203

#	Article	IF	Citations
73	Clinical Expression of Plakophilin-2 Mutations in Familial Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2006, 113, 356-364.	1.6	193
74	Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart, 2008, 94, 1478-1484.	1.2	188
75	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	1.9	188
76	Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart, 2007, 94, 1288-1294.	1.2	187
77	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary. Circulation, 2020, 142, e533-e557.	1.6	181
78	Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry Disease. American Journal of Cardiology, 2005, 96, 842-846.	0.7	180
79	Germline selection shapes human mitochondrial DNA diversity. Science, 2019, 364, .	6.0	178
80	Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2009, 2, 436-441.	5.1	176
81	A systematic review and meta-analysis of genotypeâ€“phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart, 2013, 99, 1800-1811.	1.2	172
82	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	3.9	169
83	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. Journal of the American College of Cardiology, 2007, 49, 2419-2426.	1.2	167
84	Quantification of left ventricular trabeculae using fractal analysis. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 36.	1.6	167
85	The Histological Basis of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in a Patient with Anderson-Fabry Disease. Journal of Cardiovascular Magnetic Resonance, 2006, 8, 479-482.	1.6	163
86	Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey. Heart, 2011, 97, 1957-1960.	1.2	163
87	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	1.0	163
88	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 2599-2605.	1.0	160
89	Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. Journal of the American College of Cardiology, 2005, 45, 922-930.	1.2	155
90	Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace, 2010, 12, 313-321.	0.7	155

#	Article	IF	Citations
91	Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 99.	1.6	154
92	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	1.0	154
93	Septal myotomyâ€“myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. European Heart Journal, 2002, 23, 1617-1624.	1.0	150
94	Prevalence and Clinical Significance of Cardiovascular Abnormalities in Patients With the LEOPARD Syndrome. American Journal of Cardiology, 2007, 100, 736-741.	0.7	150
95	Practical Instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal, 2018, 39, e43-e80.	1.0	149
96	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
97	Prospective Familial Assessment in Dilated Cardiomyopathy. Circulation, 2007, 115, 76-83.	1.6	148
98	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	3.0	147
99	Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. Journal of the American College of Cardiology, 2000, 36, 864-870.	1.2	146
100	The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart, 2012, 98, 116-125.	1.2	146
101	Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2010, 3, 314-322.	5.1	145
102	Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart, 2014, 100, 1851-1858.	1.2	144
103	Echocardiographic Evaluation in Asymptomatic Relatives of Patients with Dilated Cardiomyopathy Reveals Preclinical Disease. Annals of Internal Medicine, 2005, 143, 108.	2.0	134
104	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation, 2019, 140, 293-302.	1.6	131
105	A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart, 2013, 99, 534-541.	1.2	127
106	Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. European Heart Journal Cardiovascular Imaging, 2018, 19, 757-767.	0.5	126
107	Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. American Journal of Cardiology, 2000, 86, 162-168.	0.7	124
108	Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2315-2325.	1.2	124

#	Article	IF	Citations
109	Novel genotypeâ€“phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart, 2015, 101, 294-301.	1.2	124
110	European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 2018, 124, 189-203.	0.5	122
111	Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2012, 5, 156-166.	5.1	121
112	Genderâ€specific differences in major cardiac events and mortality in lamin A/C mutation carriers. European Journal of Heart Failure, 2013, 15, 376-384.	2.9	120
113	The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism Reports, 2019, 19, 100454.	0.4	120
114	Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. International Journal of Cardiology, 2014, 177, 400-408.	0.8	119
115	Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease. European Journal of Heart Failure, 2010, 12, 114-121.	2.9	117
116	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq0 0 0 rgBT /Overlock 10	2.9	114
117	Lamin and the heart. Heart, 2018, 104, 468-479.	1.2	113
118	Cardiac Involvement in Fabry Disease. Journal of the American College of Cardiology, 2021, 77, 922-936.	1.2	109
119	Prevalence of J-Point Elevation in Sudden Arrhythmic Death Syndrome Families. Journal of the American College of Cardiology, 2011, 58, 286-290.	1.2	108
120	Long-Term Outcomes in Hypertrophic Cardiomyopathy Caused by Mutations in the Cardiac Troponin T Gene. Circulation: Cardiovascular Genetics, 2012, 5, 10-17.	5.1	103
121	Pathogenesis of Cardiotoxicity Induced by Anthracyclines. Seminars in Oncology, 2006, 33, 2-7.	0.8	100
122	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2467-2475.	6.3	98
123	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
124	The Cardiomyopathy Registry of the EUREObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	1.0	94
125	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	1.2	93
126	Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. European Heart Journal Cardiovascular Imaging, 2020, 21, 326-336.	0.5	90

#	Article	IF	Citations
127	Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2016, 102, 1533-1543.	1.2	89
128	Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2017, 24, 1220-1230.	0.8	89
129	Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. Journal of the American College of Cardiology, 2020, 76, 550-559.	1.2	89
130	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	1.0	84
131	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure, 2019, 21, 955-964.	2.9	84
132	Anderson-Fabry Disease and the Heart. Progress in Cardiovascular Diseases, 2010, 52, 326-335.	1.6	83
133	Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. European Heart Journal, 2013, 34, 802-808.	1.0	83
134	Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors. PLoS ONE, 2017, 12, e0182379.	1.1	83
135	Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, Î±-dystrobrevin and FK Binding Protein-12. Molecular Genetics and Metabolism, 2004, 82, 162-166.	0.5	82
136	Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart, 2011, 97, 1744-1752.	1.2	82
137	Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2014, 7, 863-871.	1.3	80
138	Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 1022-1031.	1.6	79
139	Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart, 2007, 93, 372-374.	1.2	78
140	Clinical and genetic predictors of major cardiac events in patients with Andersonâ€“Fabry Disease. Heart, 2015, 101, 961-966.	1.2	78
141	Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 2002, 39, 455-462.	1.2	75
142	Role of Î² adrenergic receptor polymorphisms in heart failure: Systematic review and metaâ€analysis. European Journal of Heart Failure, 2008, 10, 3-13.	2.9	75
143	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	1.0	75
144	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	1.6	75

#	Article	IF	Citations
145	Abnormal Cardiac Formation in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2014, 7, 241-248.	5.1	74
146	Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and metaâ€analysis. ESC Heart Failure, 2019, 6, 1041-1051.	1.4	73
147	Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Research in Cardiology, 1999, 94, 49-59.	2.5	72
148	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. Journal of the American College of Cardiology, 2004, 44, 398-405.	1.2	72
149	Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 443-451.	2.1	72
150	Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. Journal of Medical Genetics, 2018, 55, 351-358.	1.5	72
151	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	1.2	71
152	Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. Europace, 2016, 18, 888-896.	0.7	69
153	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	3.0	69
154	Evidence From Family Studies for Autoimmunity in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2020, 141, 1238-1248.	1.6	69
155	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. American Heart Journal, 1998, 136, 972-981.	1.2	68
156	QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. American Journal of Cardiology, 1998, 82, 1514-1519.	0.7	66
157	Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. European Heart Journal, 1996, 17, 1056-1064.	1.0	65
158	Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 1075-1093.	0.5	65
159	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease â€“ A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism, 2019, 126, 224-235.	0.5	65
160	Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE120008193.	1.6	65
161	Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace, 2011, 13, 1781-1788.	0.7	63
162	Effect of biventricular pacing on symptoms and cardiac remodelling in patients with endâ€stage hypertrophic cardiomyopathy. European Journal of Heart Failure, 2008, 10, 507-513.	2.9	62

#	Article	IF	Citations
163	DPD Quantification in CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1353-1363.	2.3	61
164	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	59
165	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	1.2	59
166	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 2518-2532.	1.2	59
167	Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives. Circulation, 2019, 140, 184-192.	1.6	58
168	Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 299, 186-191.	0.8	58
169	A detailed pathologic examination of heart tissue from three older patients with Andersonâ€“Fabry disease on enzyme replacement therapy. Cardiovascular Pathology, 2010, 19, 293-301.	0.7	57
170	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	2.9	57
171	Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. European Heart Journal, 1998, 19, 500-507.	1.0	56
172	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	1.0	56
173	Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. International Journal of Cardiology, 2015, 183, 143-148.	0.8	55
174	Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. Future Cardiology, 2012, 8, 71-88.	0.5	54
175	Role of Serum N-Terminal Pro-Brain Natriuretic Peptide Measurement in Diagnosis of Cardiac Involvement in Patients With Anderson-Fabry Disease. American Journal of Cardiology, 2013, 111, 111-117.	0.7	54
176	2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 58.	0.4	54
177	Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. International Journal of Cardiology, 2019, 284, 99-104.	0.8	54
178	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 2021, 9, 115-123.	1.9	52
179	Arrhythmic Genotypes in Familial Dilated Cardiomyopathy: Implications for Genetic Testing and Clinical Management. Heart Lung and Circulation, 2019, 28, 31-38.	0.2	51
180	Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3063-3073.	1.0	51

#	Article	IF	Citations
181	How should hypertrophic cardiomyopathy be classified?. Circulation: Cardiovascular Genetics, 2009, 2, 81-86.	5.1	50
182	Fractal Analysis of Myocardial Trabeculations in 2547 Study Participants: Multi-Ethnic Study of Atherosclerosis. Radiology, 2015, 277, 707-715.	3.6	50
183	The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease â€“ A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism, 2019, 126, 212-223.	0.5	50
184	Angina pectoris and normal coronary arteriograms: Clinical presentation and hemodynamic characteristics. American Journal of Cardiology, 1995, 76, 35D-42D.	0.7	49
185	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Revista Espanola De Cardiologia (English Ed), 2016, 69, 176.	0.4	48
186	Left ventricular strain and untwist in hypertrophic cardiomyopathy: Relation to exercise capacity. American Heart Journal, 2010, 159, 825-832.	1.2	47
187	Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy. JAMA Cardiology, 2019, 4, 230.	3.0	47
188	Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. Current Cardiology Reports, 2019, 21, 155.	1.3	46
189	Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 482-486.	0.9	45
190	The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace, 2012, 14, 724-733.	0.7	45
191	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
192	Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. Journal of the American College of Cardiology, 1996, 28, 14-19.	1.2	44
193	The Binary Endocardial Appearance Is a Poor Discriminator of Anderson-Fabry Disease From Familial Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 51, 2058-2061.	1.2	44
194	Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. European Heart Journal, 2013, 34, 1002-1011.	1.0	44
195	Imaging Phenotype Versus Genotype in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2011, 4, 156-168.	1.3	43
196	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2006, 98, 515-519.	0.7	42
197	A straightforward guide to the sarcomeric basis of cardiomyopathies. Heart, 2014, 100, 1916-1923.	1.2	42
198	Lossâ€ofâ€function desmoplakin I and II mutations underlie dominant arrhythmogenic cardiomyopathy with a hair and skin phenotype. British Journal of Dermatology, 2019, 180, 1114-1122.	1.4	41

#	Article	IF	Citations
199	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	1.0	41
200	Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet, The, 2002, 360, 654-655.	6.3	40
201	Left ventricular noncompaction. Current Opinion in Cardiology, 2009, 24, 209-213.	0.8	40
202	Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace, 2010, 12, 1156-1175.	0.7	39
203	Sex-related differences in cardiomyopathies. International Journal of Cardiology, 2019, 286, 239-243.	0.8	39
204	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia, 2018, 37, 1-10.	0.2	38
205	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e001974.	1.6	38
206	Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS ONE, 2018, 13, e0193550.	1.1	38
207	Genetics of heart failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2451-2461.	1.8	37
208	A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy. Metabolomics, 2016, 12, 59.	1.4	37
209	Takotsubo is not a cardiomyopathy. International Journal of Cardiology, 2018, 254, 250-253.	0.8	37
210	Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	36
211	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiology, 2021, 6, 891.	3.0	36
212	The genetics of hypertrophic cardiomyopathy. Global Cardiology Science & Practice, 2018, 2018, 36.	0.3	36
213	Isolated left ventricular non-compaction: the case for abnormal myocardial development. Cardiology in the Young, 2007, 17, 124-129.	0.4	35
214	Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. Molecular Genetics and Metabolism, 2007, 90, 435-440.	0.5	35
215	Dynamic electrocardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy. Heart, 2010, 96, 516-522.	1.2	35
216	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 3073-3073.	1.0	34

#	Article	IF	Citations
217	Exercise-Induced Left Ventricular Outflow Tract Obstruction in Symptomatic Patients With Anderson-Fabry Disease. Journal of the American College of Cardiology, 2011, 58, 88-89.	1.2	34
218	Quantitative Expression of the Mutated Lamin A/C Gene in Patients With Cardiolaminopathy. Journal of the American College of Cardiology, 2012, 60, 1916-1920.	1.2	34
219	Prevention of sudden cardiac death in hypertrophic cardiomyopathy. Heart, 2014, 100, 254-260.	1.2	34
220	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, .	1.6	34
221	Fractal frontiers in cardiovascular magnetic resonance: towards clinical implementation. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 80.	1.6	33
222	Anderson-Fabry disease in heart failure. Biophysical Reviews, 2018, 10, 1107-1119.	1.5	33
223	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.4	33
224	Cardiomyopathy as presenting sign of glycogeninâ€1 deficiencyâ€"report of three cases and review of the literature. Journal of Inherited Metabolic Disease, 2017, 40, 139-149.	1.7	32
225	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. Heart Failure Clinics, 2018, 14, 119-128.	1.0	32
226	Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning. Molecular and Cellular Proteomics, 2020, 19, 114-127.	2.5	32
227	Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. European Heart Journal, 2022, 43, 1901-1916.	1.0	32
228	The Classification Concept of the ESC Working Group on Myocardial and Pericardial Diseases for Dilated Cardiomyopathy. Herz, 2007, 32, 446-451.	0.4	31
229	GuÃa de prÃ¡ctica clÃnica de la ESC sobre diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
230	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2019, 105, heartjnl-2018-313700.	1.2	31
231	Extracellular matrix turnover and disease severity in Andersonâ€"Fabry disease. Journal of Inherited Metabolic Disease, 2007, 30, 88-95.	1.7	30
232	Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart, 2017, 103, 300-306.	1.2	30
233	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 678-686.	0.8	30
234	Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy. European Journal of Medical Genetics, 2015, 58, 611-616.	0.7	29

#	Article	IF	Citations
235	The embryological basis of subclinical hypertrophic cardiomyopathy. Scientific Reports, 2016, 6, 27714.	1.6	29
236	European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 377-382.	1.8	29
237	Genes and disease expression in hypertrophic cardiomyopathy. Lancet, The, 1998, 352, 1162-1163.	6.3	28
238	The Novel Desmin Variant p.Leu115Ile Is Associated With a Unique Form of Biventricular Arrhythmogenic Cardiomyopathy. Canadian Journal of Cardiology, 2021, 37, 857-866.	0.8	28
239	A Novel Myosin Essential Light Chain Mutation Causes Hypertrophic Cardiomyopathy with Late Onset and Low Expressivity. Biochemistry Research International, 2012, 2012, 1-6.	1.5	27
240	Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy. Heart, 2020, 106, 1342-1348.	1.2	27
241	Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records. PLoS ONE, 2018, 13, e0191214.	1.1	27
242	Classification of Cardiomyopathies. Journal of the American College of Cardiology, 2013, 62, 2073-2074.	1.2	26
243	T Wave Complexity in Patients with Hypertrophic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2382-2386.	0.5	25
244	Cardiovascular complications of neuromuscular disorders. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 171-179.	0.4	25
245	Genetics and metabolic cardiomyopathies. Herz, 2012, 37, 598-611.	0.4	25
246	Pregnancy and its management in women with GSD type III â€•a single centre experience. Journal of Inherited Metabolic Disease, 2012, 35, 245-251.	1.7	25
247	Takotsubo Cardiomyopathy. Heart Failure Clinics, 2013, 9, 207-216.	1.0	25
248	Late-Onset Hypertrophic Cardiomyopathy Caused by a Mutation in the Cardiac Troponin T Gene. New England Journal of Medicine, 1999, 341, 1855-1856.	13.9	24
249	Dual Chamber Pacing in Hypertrophic Cardiomyopathy: Long-Term Effects on Diastolic Function. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1433-1440.	0.5	24
250	Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. Journal of Medical Genetics, 2012, 49, 212-220.	1.5	24
251	Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine, 2013, 7, 505-516.	0.6	24
252	Improving Interpretation of Cardiac Phenotypes and Enhancing Discovery With Expanded Knowledge in the Gene Ontology. Circulation Genomic and Precision Medicine, 2018, 11, e001813.	1.6	24

#	Article	IF	Citations
253	Prevalence of Sequence Variants in the RAS-Mitogen Activated Protein Kinase Signaling Pathway in Pre-Adolescent Children With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2012, 5, 317-326.	5.1	23
254	Dilated cardiomyopathy: so many cardiomyopathies!. European Heart Journal, 2020, 41, 3784-3786.	1.0	23
255	Cryptic Splice-Altering Variants in MYBPC3 Are a Prevalent Cause of Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002905.	1.6	23
256	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	1.4	23
257	Left ventricular hypertrophy caused by a novel nonsense mutation in FHL1. European Journal of Medical Genetics, 2013, 56, 251-255.	0.7	22
258	Mutations in the cardiac Troponin C gene are a cause of idiopathic dilated cardiomyopathy in childhood. Cardiology in the Young, 2007, 17, 675-7.	0.4	21
259	Cardiovascular Magnetic Resonance of Isolated Left Ventricular Apical Hypoplasia. Circulation, 2008, 117, e504-5.	1.6	21
260	A microRNA Expression Profile as Non-Invasive Biomarker in a Large Arrhythmogenic Cardiomyopathy Cohort. International Journal of Molecular Sciences, 2020, 21, 1536.	1.8	21
261	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	1.6	21
262	Reversal of Inappropriate Peripheral Vascular Responses in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 883-892.	1.2	20
263	The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines. Heart, 2009, 95, 759-760.	1.2	20
264	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 645-653.	0.8	20
265	Clinical Features and Natural History of Preadolescent Nonsyndromic HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 1986-1997.	1.2	20
266	The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Open Heart, 2014, 1, e000176.	0.9	19
267	Cardiac output response and peripheral oxygen extraction during exercise among symptomatic hypertrophic cardiomyopathy patients with and without left ventricular outflow tract obstruction. Heart, 2014, 100, 639-646.	1.2	19
268	Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 64.	1.6	19
269	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	19
270	ESC EORP Cardiomyopathy Registry: realâ€life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	1.4	19

#	Article	IF	Citations
271	Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease. EBioMedicine, 2020, 54, 102723.	2.7	19
272	Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal. EuroIntervention, 2019, 15, 411-417.	1.4	19
273	Sudden death in athletes. Clinical Medicine, 2012, 12, 253-256.	0.8	18
274	Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 2123-2134.	2.3	18
275	The 2006 American Heart Association Classification of Cardiomyopathies Is Not the Gold Standard. Circulation: Heart Failure, 2008, 1, 77-80.	1.6	17
276	Criterios diagnÃ³sticos para la miocardiopatÃa arritmogÃ©nica delÂventrÃculo derecho. Revista Espanola De Cardiologia, 2012, 65, 599-605.	0.6	17
277	135â€…Novel Hybrid Positron Emission Tomography - Magnetic Resonance (PET-MR) Multi-modality Inflammatory Imaging has Improved Diagnostic Accuracy for Detecting Cardiac Sarcoidosis. Heart, 2014, 100, A80.1-A80.	1.2	16
278	Longâ€term outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. European Journal of Heart Failure, 2018, 20, 398-405.	2.9	16
279	Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observational multicentre study. Europace, 2021, 23, 1409-1417.	0.7	16
280	Is QT Dispersion Associated with Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy?. Annals of Noninvasive Electrocardiology, 2001, 6, 209-215.	0.5	15
281	Heart Rate Recovery in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2014, 113, 1011-1017.	0.7	15
282	Community delivery of semiautomated fractal analysis tool in cardiac mr for trabecular phenotyping. Journal of Magnetic Resonance Imaging, 2017, 46, 1082-1088.	1.9	15
283	Arrhythmogenic cardiomyopathies (ACs): diagnosis, risk stratification and management. Heart, 2019, 105, 1117-1128.	1.2	15
284	Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers. Journal of the American Heart Association, 2021, 10, e020227.	1.6	15
285	PACING IN HYPERTROPHIC CARDIOMYOPATHY. Cardiology Clinics, 2000, 18, 67-79.	0.9	14
286	Myectomy Plus Alfieri Technique for Outflow Tract Obstruction in Hypertrophic Cardiomyopathy. Circulation, 2010, 122, 938-939.	1.6	14
287	Assessment of a conduction-repolarisation metric to predict Arrhythmogenesis in right ventricular disorders. International Journal of Cardiology, 2018, 271, 75-80.	0.8	14
288	Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity. Journal of Molecular Diagnostics, 2020, 22, 1205-1215.	1.2	14

#	Article	IF	Citations
289	Prevalence and clinical outcomes of dystrophinâ€associated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	2.9	14
290	Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?. European Cardiology Review, 2020, 15, 1-5.	0.7	14
291	Prognosis and prognostic factors in node-negative cervix cancer. International Journal of Gynecological Cancer, 1996, 6, 477-482.	1.2	13
292	Left Ventricular Outflow Tract Obstruction Caused by Accessory Mitral Valve Tissue. Journal of the American Society of Echocardiography, 2006, 19, 354.e5-354.e8.	1.2	13
293	Current applications of biomarkers in cardiomyopathies. Expert Review of Cardiovascular Therapy, 2015, 13, 825-837.	0.6	13
294	Right Ventricular Cardiomyopathies: A Multidisciplinary Approach to Diagnosis. Echocardiography, 2015, 32, S75-94.	0.3	13
295	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 1-10.	0.2	13
296	Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy. Molecular Genetics and Metabolism, 2019, 126, 210-211.	0.5	13
297	Deletions of specific exons of <scp>FHOD3</scp> detected by nextâ€generation sequencing are associated with hypertrophic cardiomyopathy. Clinical Genetics, 2020, 98, 86-90.	1.0	13
298	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	1.1	13
299	Sudden cardiac death in hypertrophic cardiomyopathy: time to change the narrative. European Heart Journal, 2021, 42, 3945-3947.	1.0	13
300	The molecular genetics of hypertrophic cardiomyopathy: prognostic implications. Europace, 2000, 2, 4-14.	0.7	12
301	Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2012, 65, 599-605.	0.4	12
302	Psychosocial adjustment and quality of life in children undergoing screening in a specialist paediatric hypertrophic cardiomyopathy clinic. Cardiology in the Young, 2016, 26, 961-967.	0.4	12
303	Why systematic literature reviews in Fabry disease should include all published evidence. European Journal of Medical Genetics, 2019, 62, 103702.	0.7	12
304	Biventricular pacemaker therapy improves exercise capacity in patients with nonâ€obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise. European Journal of Heart Failure, 2020, 22, 1263-1272.	2.9	12
305	Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 1999, 282, 2302-2303.	3.8	12
306	Current management of hypertrophic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 496-504.	0.4	11

#	Article	IF	Citations
307	New approaches to the clinical diagnosis of inherited heart muscle disease. Heart, 2013, 99, 1451-1461.	1.2	11
308	Early and medium-term outcomes of Alfieri mitral valve repair in the management of systolic anterior motion during septal myectomy. Journal of Cardiac Surgery, 2017, 32, 686-690.	0.3	11
309	Isolated aortic root dilation in homocystinuria. Journal of Inherited Metabolic Disease, 2018, 41, 109-115.	1.7	11
310	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Failure, 2020, 7, 3601-3609.	1.4	11
311	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiologyâ€"Cardiovascular Round Table. Cardiovascular Research, 2021, 117, 1248-1256.	1.8	11
312	Contemporary and Future Approaches toÂPrecision Medicine in InheritedÂCardiomyopathies. Journal of the American College of Cardiology, 2021, 77, 2551-2572.	1.2	11
313	Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 9, 42-53.	1.8	11
314	Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study. Heart, 2022, 108, 1383-1391.	1.2	11
315	A case of infective endocarditis in a farmer caused by Streptococcus equinus. European Heart Journal, 1993, 14, 1292-1293.	1.0	10
316	Evolution and Clinical Importance of Fibrosis in HCM. JACC: Cardiovascular Imaging, 2011, 4, 1221-1223.	2.3	10
317	Impact of Measures to Enhance the Value of Observational Surveys in Rare Diseases: The Fabry Outcome Survey (FOS). Value in Health, 2011, 14, 862-866.	0.1	10
318	Prevalence of TTR variants detected by whole-exome sequencing in hypertrophic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 243-247.	1.4	10
319	The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM. Cardiovascular Research, 2020, 116, e175-e178.	1.8	10
320	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. European Heart Journal Cardiovascular Imaging, 2021, 22, 781-789.	0.5	10
321	Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. Molecular Genetics and Metabolism, 2021, 132, 234-243.	0.5	10
322	Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease. Journal of Cardiovascular Echography, 2018, 28, 120.	0.1	10
323	Prognosis of idiopathic dilated cardiomyopathy. Journal of Cardiac Failure, 1995, 1, 337-345.	0.7	9
324	Can the Assessment of Dynamic QT Dispersion on Exercise Electrocardiogram Predict Sudden Cardiac Death in Hypertrophic Cardiomyopathy?. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1953-1956.	0.5	9

#	Article	IF	Citations
325	The Science of Uncertainty and the Art of Probability. Circulation, 2009, 119, 1697-1699.	1.6	9
326	ST Segment â€œHumpâ€•during Exercise Testing and the Risk of Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy. Annals of Noninvasive Electrocardiology, 2009, 14, 158-164.	0.5	9
327	Clinical utility gene card for: hypertrophic cardiomyopathy (type 1â€“14). European Journal of Human Genetics, 2011, 19, 3-4.	1.4	9
328	Nonâ€invasive assessment of cardiac output at rest and during exercise by finger plethysmography. Clinical Physiology and Functional Imaging, 2013, 33, 338-343.	0.5	9
329	The structural effects of mutations can aid in differential phenotype prediction of beta-myosin heavy chain (Myosin-7) missense variants. Bioinformatics, 2016, 32, 2947-2955.	1.8	9
330	Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement. Journal of Cardiovascular Medicine, 2017, 18, 249-254.	0.6	9
331	Outcomes following the surgical management of left ventricular outflow tract obstruction; A systematic review and meta-analysis. International Journal of Cardiology, 2018, 265, 62-70.	0.8	9
332	Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease. International Journal of Molecular Sciences, 2020, 21, 5784.	1.8	9
333	2015 ESC GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH VENTRICULAR ARRHYTHMIAS AND THE PREVENTION OF SUDDEN CARDIAC DEATH. Russian Journal of Cardiology, 2016, , 5-86.	0.4	9
334	Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy. Current Pharmaceutical Design, 2014, 21, 466-472.	0.9	9
335	Left atrial volume during stress is associated with increased risk of arrhythmias in patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Echography, 2019, 29, 1.	0.1	9
336	Subclinical skeletal muscle abnormalities in patients with hypertrophic cardiomyopathy and their relation to clinical characteristics. International Journal of Cardiology, 2003, 89, 249-256.	0.8	8
337	Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 711-713.	0.6	8
338	CardioPulse ArticlesThe 2014 ESC Guidelines on the Diagnosis and Management of Hypertrophic Cardiomyopathy have been publishedThe â€˜Ten Commandmentsâ€™ of the ESC Hypertrophic Cardiomyopathy GuidelinesEuroPCR 2014, Hypertension and Heart Failure Track take-home messagesTales from another career: Douglas W. Losordo MDThe Kyrgyz Society of Cardiologists and Structure of Cardiology Services in Kyrgyzstan. European Heart Journal, 2014, 35, 2849-2854.	1.0	8
339	Management of aortic stenosis in mucopolysaccharidosis type I. International Journal of Cardiology, 2014, 172, e430-e431.	0.8	8
340	Almanac 2014: cardiomyopathies. Heart, 2014, 100, 756-764.	1.2	8
341	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 1410-1411.	1.2	8
342	Individualized surgical strategies for left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. European Journal of Cardio-thoracic Surgery, 2018, 53, 1237-1243.	0.6	8

#	Article	IF	Citations
343	Corrigendum to: 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal, 2018, 39, 2002-2002.	1.0	8
344	Left ventricular non-compaction: have we reached the limits of conventional imaging?. European Heart Journal, 2020, 41, 1437-1438.	1.0	8
345	The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individuals. European Journal of Medical Genetics, 2020, 63, 104079.	0.7	8
346	Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population. JAMA Cardiology, 2021, 6, 852.	3.0	8
347	A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction DiseaseÂin Patients With Myotonic Dystrophy Type 1. JACC: Clinical Electrophysiology, 2021, 7, 1038-1048.	1.3	8
348	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010075.	2.1	8
349	Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. European Heart Journal, 1997, 18, 1946-1950.	1.0	7
350	Arrhythmogenic right ventricular cardiomyopathy as a hidden cause of paediatric myocarditis presentation. International Journal of Cardiology, 2018, 271, 113-114.	0.8	7
351	Diagnostic Impact of Repeated Expert Review & Longâ€Term Followâ€Up in Determining Etiology of Idiopathic Cardiac Arrest. Journal of the American Heart Association, 2021, 10, e019610.	1.6	7
352	Tissue doppler features of cardiac amyloidosis. Clinical Cardiology, 2000, 23, 701-701.	0.7	6
353	Optimization of concomitant medication in Fabry cardiomyopathy. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 81-83.	0.7	6
354	94â€...Percutaneous Mitral Repair in Hypertrophic Cardiomyopathy: Abstract 94 Table 1. Heart, 2014, 100, A54-A55.	1.2	6
355	Affairs of the heart: outcomes in men and women with hypertrophic cardiomyopathy. European Heart Journal, 2017, 38, 3441-3433.	1.0	6
356	CardioScape mapping the cardiovascular funding landscape in Europe. European Heart Journal, 2018, 39, 2423-2430.	1.0	6
357	Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1399-1401.	1.6	6
358	Impact of left bundle branch block (LBBB) in dilated cardiomyopathy (DCM) with intermediate left ventricular systolic dysfunction (LVSD). International Journal of Cardiology, 2019, 278, 199-201.	0.8	6
359	The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease. European Heart Journal, 2020, 41, 3113-3116.	1.0	6
360	The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. Current Cardiology Reports, 2001, 3, 167-172.	1.3	5

#	Article	IF	Citations
361	Hypertrophic cardiomyopathy: a 50th anniversary. Heart, 2007, 94, 1247-1248.	1.2	5
362	Genetic aspects and investigation of sudden death in young people. Clinical Medicine, 2008, 8, 607-610.	0.8	5
363	How should hypertrophic cardiomyopathy be classified?. Circulation: Cardiovascular Genetics, 2009, 2, 87-89.	5.1	5
364	Right ventricular hypertrabeculation associated with double-outlet left ventricle: exaggeration of a normal pattern or right ventricular cardiomyopathy?. Journal of Cardiovascular Medicine, 2010, 11, 193-195.	0.6	5
365	Enzyme replacement therapy for Fabry's disease â€“ Authors' reply. Lancet, The, 2010, 375, 1523-1524.	6.3	5
366	Improving the diagnostic accuracy for detecting cardiac sarcoidosis. Expert Review of Cardiovascular Therapy, 2015, 13, 223-236.	0.6	5
367	Defining Tachycardia-Induced Cardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 2173-2174.	1.2	5
368	Evolving Story of Clinical Trials in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004572.	1.6	5
369	The prevention of sudden death in hypertrophic cardiomyopathy. Expert Opinion on Pharmacotherapy, 2002, 3, 499-504.	0.9	4
370	Hypertrophic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2010, 2, 587-598.	0.7	4
371	Beyond sudden death in the athlete: how to identify family members at risk. British Journal of Sports Medicine, 2011, 45, 189-192.	3.1	4
372	Risk stratification in hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2013, 14, 319-325.	0.6	4
373	GuÃa de prÃ¡ctica clÃnica de la ESC 2013 sobre estimulaciÃ³n cardiaca y terapia de resincronizaciÃ³n cardiaca. Revista Espanola De Cardiologia, 2014, 67, 58.e1-58.e60.	0.6	4
374	A Family History of Sudden Death Should Not Be a Primary Indication for an Implantable Cardioverter Defibrillator inÂHypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2015, 31, 1407-1409.	0.8	4
375	Rare Disease in Cardiovascular Medicine I. European Heart Journal, 2017, 38, 1625-1628.	1.0	4
376	Rare Diseases in Cardiovascular Medicine II. European Heart Journal, 2017, 38, 1629-1631.	1.0	4
377	Personalized medicine for dilated cardiomyopathy. European Heart Journal, 2021, 42, 175-177.	1.0	4
378	The genetics of left ventricular noncompaction. Current Opinion in Cardiology, 2021, 36, 301-308.	0.8	4

#	Article	IF	Citations
379	Wytyczne ESC dotyczÄ...ce stymulacji serca i terapii resynchronizujÄ...cej w 2013 roku. Kardiologia Polska, 2013, 71, 133-192.	0.3	4
380	Changing concepts in heart muscle disease: the evolving understanding of hypertrophic cardiomyopathy. Heart, 2022, 108, 768-773.	1.2	4
381	Natural history of hypertrophic cardiomyopathy. Current Cardiology Reports, 2000, 2, 141-147.	1.3	3
382	Sudden death and hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 1975-1976.	6.3	3
383	Evident, but poorly defined: left ventricular hypertrabeculation/noncompaction and its diagnostic criteria: reply. European Heart Journal, 2005, 26, 1144-1145.	1.0	3
384	Investigation and treatment of hypertrophic cardiomyopathy. Clinical Medicine, 2007, 7, 383-387.	0.8	3
385	Acute Myocardial Ischemia Associated with Latent Left Ventricular Outflow Tract Obstruction in the Absence of Left Ventricular Hypertrophy. Journal of the American Society of Echocardiography, 2007, 20, 772.e1-772.e4.	1.2	3
386	The quantification and role of diffuse myocardial fibrosis in familial dilated cardiomyopathy - an equilibrium contrast cmr study. Journal of Cardiovascular Magnetic Resonance, 2011, 13, .	1.6	3
387	Takotsubo: One, no one and one hundred thousand diseases. International Journal of Cardiology, 2018, 261, 35.	0.8	3
388	Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiology, 2019, 15, 53-61.	0.5	3
389	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	1.8	3
390	Hidden in Heart Failure. European Cardiology Review, 2019, 14, 89-96.	0.7	3
391	P2911 N terminal pro-brain naturetic peptide levels predict poor exercise capacity in hypertrophic cardiomyopathy. European Heart Journal, 2003, 24, 560.	1.0	3
392	OUP accepted manuscript. European Heart Journal, 2022, , .	1.0	3
393	Management strategies in hypertrophic cardiomyopathy: influence of age and morphology. European Heart Journal Supplements, 2001, 3, L10-L14.	0.0	2
394	Cardiac resynchronization therapy: the procedure and progress so far. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 469-473.	0.2	2
395	Provokable left ventricular outflow tract obstruction in a patient without hypertrophy. Nature Reviews Cardiology, 2009, 6, 313-316.	6.1	2
396	A case of transient hypertrophic cardiomyopathy. Postgraduate Medical Journal, 2010, 86, 310-312.	0.9	2

#	Article	IF	Citations
397	The Role of Alcohol Septal Ablation in the Treatment of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2011, 58, 2329-2331.	1.2	2
398	Time for education in cardiogenetics. Neurology International, 2011, 1, 2.	0.2	2
399	A case of necrotizing myopathy with proximal weakness and cardiomyopathy. Neurology, 2012, 78, 1527-1532.	1.5	2
400	Restrictive Cardiomyopathy and Hypertrophic Cardiomyopathy Overlap: The Importance of the Phenotype. Neurology International, 2012, 2, e10.	0.2	2
401	126â€...Advanced Assessment of Cardiac Morphology and Prediction of Gene Carriage by CMR in Hypertrophic Cardiomyopathy - The HCMNET/UCL Collaboration. Heart, 2014, 100, A72-A73.	1.2	2
402	The New European Society of Cardiology guidelines on hypertrophic cardiomyopathy. Heart, 2015, 101, 506-508.	1.2	2
403	Sudden cardiac death in inherited cardiomyopathy. International Journal of Cardiology, 2017, 237, 56-59.	0.8	2
404	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. Future Cardiology, 2017, 13, 521-527.	0.5	2
405	On the Road from Gene to Therapy in Inherited Cardiomyopathies. Heart Failure Clinics, 2018, 14, xi-xv.	1.0	2
406	Cardiomyopathies in children: Mitochondrial and storage disease. Progress in Pediatric Cardiology, 2018, 51, 16-23.	0.2	2
407	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	1.1	2
408	Cardiac manifestations of McArdle disease. European Heart Journal, 2019, 40, 397-398.	1.0	2
409	Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 209-210.	0.8	2
410	1â€...The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2021, , .		2
411	Iterative Reanalysis of Hypertrophic Cardiomyopathy Exome Data Reveals Causative Pathogenic Mitochondrial DNA Variants. Circulation Genomic and Precision Medicine, 2021, 14, e003388.	1.6	2
412	No re-appraisal of non-compaction diagnostic criteria without considering neurological co-morbidity and genetic heterogeneity: reply. European Heart Journal, 2008, 29, 951-952.	1.0	2
413	The Safety and Feasibility of Transitioning From Transfemoral to Transradial Access Left Ventricular Endomyocardial Biopsy. Journal of Invasive Cardiology, 2020, 32, E349-E354.	0.4	2
414	Hypertrophic cardiomyopathy. Evidence-based Cardiovascular Medicine, 1998, 2, 89-91.	0.0	1

#	Article	IF	Citations
415	Relevance of platelet activation in obstructive hypertrophic cardiomyopathy. Heart, 2008, 94, 688-689.	1.2	1
416	The new European definition of cardiomyopathies: which space for muscle dystrophies?: reply. European Heart Journal, 2008, 29, 1592-1592.	1.0	1
417	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Heart, 2011, 97, 1914-1919.	1.2	1
418	The collapsing pulse. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, C78-C80.	0.2	1
419	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa De Cardiologia, 2012, 31, 255-261.	0.2	1
420	Advanced assessment of cardiac morphology and prediction of gene carriage by CMR in hypertrophic cardiomyopathy - the HCMNet/UCL collaboration. Journal of Cardiovascular Magnetic Resonance, 2014, 16, O30.	1.6	1
421	Bâ€…Embryogenesis of Ventricular Myocardial Trabeculae â€“ Novel Insights from Episcopic 3D Imaging and Fractal Analysis of Wild-type and Notch MIB1 Noncompaction Mouse Models. Heart, 2014, 100, A125-A128.	1.2	1
422	Almanac 2014: Cardiomyopathies.. Cardiologia Croatica, 2015, 9, 543-557.	0.0	1
423	Fabry Disease. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	1
424	Non-sustained Ventricular Tachycardia and Sudden Death in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 1998, 31, 26A.	1.2	1
425	P1553 Depolarisation and repolarisation heterogeneity in arrhythmogenic right-ventricular cardiomyopathy. European Heart Journal, 2003, 24, 281.	1.0	1
426	Diseases of the Myocardium and Endocardium. , 2012, , 318-333.		1
427	Tafamidis Reduces The Decline In Longitudinal Strain And Stroke Volume In Patients With Transthyretin Amyloid Cardiomyopathy. Journal of Cardiac Failure, 2022, 28, S102-S103.	0.7	1
428	Interpretation of genetic variants depends on a clinically guided integration of phenotype and molecular data. European Heart Journal, 2022, 43, 2638-2639.	1.0	1
429	Treatment for heart failure: good news and bad. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.2	0
430	Alcoholic cardiomyopathy. Drug Discovery Today: Disease Models, 2005, 2, 227-231.	1.2	0
431	Extracellular matrix turnover and disease severity in Andersonâ€“Fabry disease. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 118-123.	0.7	0
432	G.P.5.09 Severe necrotising myopathy and cardiomyopathy with anti-signal recognition peptide antibodies. Neuromuscular Disorders, 2008, 18, 771-772.	0.3	0

#	Article	IF	Citations
433	PSY2 CONTRIBUTIONS OF THE FABRY OUTCOME SURVEY (FOS) TO ADVANCING THE MANAGEMENT OF FABRY DISEASE. Value in Health, 2008, 11, A628-A629.	0.1	0
434	Natural history and familial characteristics of isolated left ventricular non-compaction. European Heart Journal, 2008, 29, 1925-1925.	1.0	0
435	What do tachycardiomyopathy belong to?: reply. European Heart Journal, 2008, 29, 1074-1074.	1.0	0
436	The quest for perfection: the contribution of the electrocardiogram to the prevention of sudden death in hypertrophic cardiomyopathy. Europace, 2009, 11, 548-549.	0.7	0
437	061â€...Metabolic alteration in hypertrophic cardiomyopathy (METAL-HCM Study): randomised double blinded placebo controlled trial of perhexiline therapy in patient with hypertrophic cardiomyopathy. Heart, 2010, 96, A36.2-A36.	1.2	0
438	Equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
439	Corrigendum to â€˜Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain diseaseâ€™ [Eur J Heart Fail2010;12:114-121]. European Journal of Heart Failure, 2010, 12, 1017-1017.	2.9	0
440	Cardiac manifestations of mitochondrial disorders: reply. European Journal of Heart Failure, 2010, 12, 637-638.	2.9	0
441	092â€...Interstitial expansion in health and diseaseâ€”an equilibrium contrast CMR study. Heart, 2012, 98, A53-A54.	1.2	0
442	073â€...Evaluation of clinical markers of early disease expression and the ability to predict genotype in families with HCM and mutations in cardiac myosin binding protein C. Heart, 2012, 98, A41.2-A42.	1.2	0
443	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 255-261.	0.2	0
444	Interstitial expansion in health and disease - an equilibrium contrast CMR study. Journal of Cardiovascular Magnetic Resonance, 2012, 14, .	1.6	0
445	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Egyptian Heart Journal, 2012, 64, 17-24.	0.4	0
446	88â€...Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Heart, 2014, 100, A50.3-A51.	1.2	0
447	Paving the Way for Novel Treatment Strategies in Genetic Cardiomyopathiesâˆ—. Journal of the American College of Cardiology, 2014, 64, 2777-2778.	1.2	0
448	153â€...Novel Insights into the Pathophysiology of Hypertrophic Cardiomyopathy Using Label free Quantitative Proteomics. Heart, 2014, 100, A89-A90.	1.2	0
449	101â€...Ethnic Variation in Hypertrophic Cardiomyopathy. Heart, 2015, 101, A58.1-A58.	1.2	0
450	Almanac 2014: cardiomyopathies. Cor Et Vasa, 2015, 57, e28-e38.	0.1	0

#	Article	IF	Citations
451	CMR detects abnormal septal convexity into the left ventricle in preclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P274.	1.6	0
452	123â€...The Development of a Dietary Preparation Protocol for Optimal Inflammatory Imaging Using 18F-FDG PET. Heart, 2016, 102, A87.1-A87.	1.2	0
453	122â€...Introduction of Stress Only Myocardial Perfusion Scintigraphy: A Quality Improvement Programme. Heart, 2016, 102, A86.2-A87.	1.2	0
454	It's not just the mitral valve - abnormal motion of the whole aorto-mitral apparatus occurs in both overt and subclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2016, 18, Q37.	1.6	0
455	Structural and Biophysical Analysis of Hypertrophic Cardiomyopathy-Linked Titin Missense Variants. Biophysical Journal, 2017, 112, 164a.	0.2	0
456	TITIN Variants in Genetic Myopathies and Cardiomyopathies- Structural and Biophysical Characterization of Pathogenic Mutations. Biophysical Journal, 2018, 114, 313a.	0.2	0
457	Multifocal ectopic Purkinje-related premature contractions: Sorting the wheat from the chaff. International Journal of Cardiology, 2018, 257, 218-219.	0.8	0
458	Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results. Journal of Cardiac Failure, 2018, 24, 813.	0.7	0
459	3â€...SPECT/CT quantification of DPD scintigraphy in cardiac amyloid. , 2018, , .		0
460	CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscular Disorders, 2018, 28, S131.	0.3	0
461	The Cardiomyopathies. , 2018, , 577-617.		0
462	Transforming care for rare and inherited cardiovascular diseases through education and training. International Journal of Cardiology, 2018, 257, 342-343.	0.8	0
463	McARDLE DISEASE. Neuromuscular Disorders, 2019, 29, S82.	0.3	0
464	P.123Frequency of coronary artery disease in people with McArdle disease. Neuromuscular Disorders, 2019, 29, S84.	0.3	0
465	Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Molecular Genetics and Metabolism Reports, 2019, 20, 100493.	0.4	0
466	Hypertrophic Cardiomyopathyâ€"Need for Gene-Specific Treatment?â€"Reply. JAMA Cardiology, 2019, 4, 831.	3.0	0
467	Reply. Journal of the American College of Cardiology, 2019, 73, 1366-1367.	1.2	0
468	Sudden Cardiac Death Risk Assessment. , 2019, , 145-155.		0

#	Article	IF	Citations
469	Long-term Survival Benefit of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy. Journal of Cardiac Failure, 2020, 26, S64-S65.	0.7	0
470	Cardiogenetics: An Open Access Journal. Neurology International, 2020, 10, 42-44.	0.2	0
471	Concerns About the HCM Risk-Kids Studyâ€"Reply. JAMA Cardiology, 2020, 5, 363.	3.0	0
472	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 925-925.	3.9	0
473	Almanac 2011: Cardiomyopathies. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology. Acta Informatica Medica, 2011, 19, 235.	0.5	0
474	The dilemma of an incidental preoperative electrocardiogram showing a Brugada phenotype. BMJ Case Reports, 2011, 2011, bcr0620114418-bcr0620114418.	0.2	0
475	Cardiomyopathies the national society journals present selected research that has driven recent advances in clinical cardiology. Srce I Krvni Sudovi, 2012, 31, 174-180.	0.1	0
476	Risk Stratification in Patients with Hypertrophic Cardiomyopathy. Developments in Cardiovascular Medicine, 1998, , 83-88.	0.1	0
477	Outcome of Patients With Hypertrophic Cardiomyopathy that Survive Cardiac Arrest. Journal of the American College of Cardiology, 1998, 31, 245A.	1.2	0
478	Metabolic Exercise Testing in Hypertrophic Cardiomyopathy: Relation of Submaximal Parameters to Clinical Features. Journal of the American College of Cardiology, 1998, 31, 484A.	1.2	0
479	Relation of Left Ventricular Hypertrophy to Survival in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 1998, 31, 26A.	1.2	0
480	Clinical and Prognostic Assessment of Left Ventricular Mass in Hypertrophic Cardiomyopathy Using Three-dimensional Echocardiography. Journal of the American College of Cardiology, 1998, 31, 245A.	1.2	0
481	Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice. Current Pharmaceutical Design, 2014, 21, 515-524.	0.9	0
482	124â€...The Use of Next Generation Sequencing to Determine Genotype-Phenotype Correlations in Dilated Cardiomyopathy. Heart, 2016, 102, A87.2-A88.	1.2	0
483	Cardioskeletal Myopathies: Foreword. , 2017, , xv.		0
484	Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies. , 2018, , 259-317.		0
485	Structural and biophysical characterisation of titin missense variants in genetic myopathies and cardiomyopathies. Acta Crystallographica Section A: Foundations and Advances, 2018, 74, e424-e424.	0.0	0
486	Foreword to the Special Issue: HCM in 2018. Global Cardiology Science & Practice, 2018, 2018, 37.	0.3	0

#	Article	IF	Citations
487	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Turk Kardiyoloji Dernegi Arsivi, 2012, 40, 76-84.	0.6	0
488	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Archivos De Cardiologia De Mexico, 2012, 82, 59-65.	0.1	0
489	Reply. JACC: Clinical Electrophysiology, 2021, 7, 1625.	1.3	0
490	Pathophysiology and Significance of Myocardial Ischemia in Hypertrophic Cardiomyopathy. , 0, , 172-184.		0
491	Reversal of acute pulmonary oedema with beta-blockers in hypertrophic cardiomyopathy. European Journal of Echocardiography, 2003, 4, 71-2.	2.3	0
492	Recommendations for addressing the translational gap between experimental and clinical research on amyloid diseases. Journal of Translational Medicine, 2022, 20, 213.	1.8	0